Galecto Corp - GLTO Net Assets per Single Share

Graphic logo of Galecto, Inc. (GLTO)

Galecto, Inc. (GLTO) drug development for cancer and fibrosis remains independent of macroeconomic trends, as confirmed by the key book value metric on GURU.Markets, where the current level is approximately 4.98. High scaling potential through contract synthesis enables the company to capture global markets. The business is currently focusing on clinical trials of innovative galectin inhibitors to combat tissue scarring.

Galecto Inc (GLTO): Share Book Value from 07/04/2022 to 03/10/2026

galecto.com - analytical breakdowns and key metrics (GLTO)

- price and consensus price forecast:
Stock Quotes Galecto Corp|GLTO - Analyst Forecast Prices
- market capitalization data:
Market Value Galecto, Inc.|GLTO - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Galecto|GLTO - Net Asset Value|Market Capitalization to Book Value Ratio galecto.com|GLTO - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Galecto, Inc.|GLTO - Long-Term Debt to Capital|Short-Term Debt to Equity Galecto|GLTO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Galecto, Inc.
Fundamental company valuation:Galecto Corp - GLTO
Manufactured products of Galecto

This indicator determines the intrinsic value of the business by measuring the residual capital per share after the full settlement of all liabilities. By analyzing the trend of the book value per share, an investor assesses the actual asset backing of Galecto, Inc. (GLTO), which is critical during cost optimization and while awaiting results for the GB1211 drug for liver cancer therapy.

Competitors of Galecto, Inc. (GLTO)

Accounting Value per Share Ascendis Pharma Inc. ASND|MDGL: Book Price of a Share|Net Assets per Single Share CORT|RYTM (rhythmtx.com) - Net Asset Value per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Quince Therapeutics, Inc. (QNCX) - Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share Agape ATP Corporation (ATPC)|Net Assets per Single Share PLUR (pluri-biotech.com)|SYBX: Net Assets per Single Share|Lipocine Inc - Net Asset Value per Share|MTNB - Net Assets per Single Share|SPRB - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS